NCCN Task Force Report: Bone Health in Cancer Care

J Natl Compr Canc Netw. 2009 Jun;7 Suppl 3(Suppl 3):S1-32; quiz S33-5. doi: 10.6004/jnccn.2009.0076.

Abstract

Bone health and maintenance of bone integrity are important components of comprehensive cancer care in both early and late stages of disease. Risk factors for osteoporosis are increased in patients with cancer, including women with chemotherapy-induced ovarian failure, those treated with aromatase inhibitors for breast cancer, men receiving androgen-deprivation therapy for prostate cancer, and patients undergoing glucocorticoid therapy. The skeleton is a common site of metastatic cancer recurrence, and skeletal-related events are the cause of significant morbidity. The National Comprehensive Cancer Network (NCCN) convened a multidisciplinary task force on Bone Health in Cancer Care to discuss the progress made in identifying effective screening and therapeutic options for management of treatment-related bone loss; understanding the factors that result in bone metastases; managing skeletal metastases; and evolving strategies to reduce bone recurrences. This report summarizes presentations made at the meeting.

Publication types

  • Consensus Development Conference
  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Antineoplastic Agents, Hormonal / adverse effects
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Bone Density Conservation Agents / therapeutic use
  • Bone Neoplasms / pathology
  • Bone Neoplasms / prevention & control*
  • Bone Neoplasms / secondary
  • Bone Neoplasms / therapy
  • Breast Neoplasms / complications
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Diagnostic Imaging / methods
  • Diphosphonates / therapeutic use
  • Female
  • Humans
  • Male
  • Mass Screening / methods
  • Osteoporosis / chemically induced
  • Osteoporosis / drug therapy
  • Osteoporosis / pathology
  • Osteoporosis / prevention & control*
  • Prostatic Neoplasms / complications
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Risk Assessment

Substances

  • Antineoplastic Agents, Hormonal
  • Bone Density Conservation Agents
  • Diphosphonates